Related Experiment Video
Updated: Jan 1, 2026
07:13
Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity
Published on: January 6, 2015
11.0K
Zileuton use and phenotypic features in asthma.
P Thalanayar Muthukrishnan1, M Nouraie2, A Parikh3
1Department of Medicine, University of Pittsburgh Medical Center McKeesport, PA, USA.
Pulmonary Pharmacology & Therapeutics
|December 17, 2019
Summary
Zileuton response in asthma varies by patient type. Severe asthma and obesity were linked to poorer response rates, suggesting targeted use for non-severe asthma patients.
Area of Science:
- Pulmonology
- Pharmacology
- Immunology
Background:
- Zileuton is a 5-lipoxygenase (5LPO) inhibitor impacting the arachidonic acid pathway.
- It reduces inflammatory leukotriene production, showing potential for complex asthma cases.
- However, studies indicate only modest response rates in general asthma populations.
Purpose of the Study:
- To investigate if patient response to zileuton differs across distinct asthma phenotypes.
- To identify specific asthmatic characteristics associated with varying zileuton efficacy.
Main Methods:
- Retrospective analysis of 129 asthma patients prescribed zileuton.
- Detailed lung function and usage data analyzed for 75 patients.
- Responder status defined by ≥5% annualized increase in post-bronchodilator FEV1%.
Main Results:
- 28% of patients (21/75) met the responder criteria.
- Severe asthma was significantly associated with lower response rates (OR 0.12; p=0.004).
- Obesity showed a trend towards lower response, but did not reach statistical significance (OR 0.46; p=0.15).
Conclusions:
- Zileuton efficacy varies among asthma patients, with severe asthma and potentially obesity linked to poorer outcomes.
- Despite current trends, zileuton may be more effective in non-severe asthma.
- Consideration of zileuton alongside Leukotriene Receptor Antagonists (LTRAs) for non-severe asthma is suggested.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:26Asthma-II: Pathophysiology and Classification
4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K
01:30Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
01:20Asthma: Pathogenesis and Management
1.1K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.1K
01:24Antiasthma Drugs: Methylxanthines
1.5K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
1.5K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K